Multiple Sclerosis: B Cells Take Center Stage.
作者信息
Pröbstel Anne-Katrin, Hauser Stephen L
机构信息
Multiple Sclerosis Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
出版信息
J Neuroophthalmol. 2018 Jun;38(2):251-258. doi: 10.1097/WNO.0000000000000642.
Abstract
摘要
相似文献
1
Multiple Sclerosis: B Cells Take Center Stage.多发性硬化症：B细胞成为焦点。
J Neuroophthalmol. 2018 Jun;38(2):251-258. doi: 10.1097/WNO.0000000000000642.
2
Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.利妥昔单抗可有效清除多发性硬化症患者体内增多的表达CD20的T细胞。
J Immunol. 2014 Jul 15;193(2):580-586. doi: 10.4049/jimmunol.1400118. Epub 2014 Jun 13.
3
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives.在多发性硬化症治疗方案中采用针对 CD20 靶点的 B 细胞耗竭：现状与未来展望。
Autoimmun Rev. 2019 Jul;18(7):665-672. doi: 10.1016/j.autrev.2019.05.003. Epub 2019 May 3.
4
CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?多发性硬化症和实验性自身免疫性脑脊髓炎中的 CD20 疗法 - 靶向 T 细胞还是 B 细胞？
Mult Scler Relat Disord. 2016 Sep;9:110-7. doi: 10.1016/j.msard.2016.07.011. Epub 2016 Jul 20.
5
Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.在多发性硬化症的发病机制中，促炎性 CD20+ T 细胞发挥了作用。
Brain. 2019 Jan 1;142(1):120-132. doi: 10.1093/brain/awy301.
6
B cell depletion in the treatment of multiple sclerosis.B 细胞耗竭在多发性硬化症治疗中的应用。
Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23.
7
B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model.B 细胞耗竭可消除抗体非依赖性普通狨猴实验性自身免疫性脑脊髓炎模型中的 T 细胞介导的脱髓鞘作用。
J Neuropathol Exp Neurol. 2012 Aug;71(8):716-28. doi: 10.1097/NEN.0b013e3182622691.
8
Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells.B 细胞耗竭通过减少抗原呈递和辅助 T 细胞来诱导小鼠自身免疫性肝炎缓解。
Hepatology. 2015 Nov;62(5):1511-23. doi: 10.1002/hep.27991. Epub 2015 Sep 2.
9
CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination.CD20+炎性T细胞存在于多发性硬化症患者的血液和大脑中，并且可以被选择性地靶向用于凋亡清除。
Mult Scler Relat Disord. 2014 Sep;3(5):650-8. doi: 10.1016/j.msard.2014.06.001. Epub 2014 Jun 12.
10
Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.一名患有多发性硬化症且因使用阿仑单抗导致T淋巴细胞亚群严重耗竭的患者发生轻度新型冠状病毒肺炎感染。
Mult Scler Relat Disord. 2020 Sep;44:102314. doi: 10.1016/j.msard.2020.102314. Epub 2020 Jun 20.
引用本文的文献
1
Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study.多发性硬化症与肠道微生物群：来自多发性硬化症双胞胎回肠的毛螺菌科在无菌转基因小鼠中引发类似多发性硬化症的疾病——一项无偏倚的功能研究。
Proc Natl Acad Sci U S A. 2025 May 6;122(18):e2419689122. doi: 10.1073/pnas.2419689122. Epub 2025 Apr 21.
2
IRF5 mediates adaptive immunity via altered glutamine metabolism, mTORC1 signaling and post-transcriptional regulation following T cell receptor activation.在T细胞受体激活后，IRF5通过改变谷氨酰胺代谢、mTORC1信号传导和转录后调控来介导适应性免疫。
bioRxiv. 2024 Aug 27:2024.08.26.609422. doi: 10.1101/2024.08.26.609422.
3
Current Knowledge about CD3CD20 T Cells in Patients with Multiple Sclerosis.多发性硬化症患者中 CD3CD20 T 细胞的现有知识。
Int J Mol Sci. 2024 Aug 18;25(16):8987. doi: 10.3390/ijms25168987.
4
Gene expression and alternative splicing analysis in a large-scale Multiple Sclerosis study.一项大规模多发性硬化症研究中的基因表达与可变剪接分析
medRxiv. 2024 Aug 16:2024.08.16.24312099. doi: 10.1101/2024.08.16.24312099.
5
Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An study.工程化嵌合自身抗体受体T细胞用于多发性硬化症模型中的靶向B细胞耗竭：一项研究。
Heliyon. 2023 Sep 1;9(9):e19763. doi: 10.1016/j.heliyon.2023.e19763. eCollection 2023 Sep.
6
Proteolipid Protein-Induced Mouse Model of Multiple Sclerosis Requires B Cell-Mediated Antigen Presentation.载脂蛋白诱导的多发性硬化症小鼠模型需要 B 细胞介导的抗原呈递。
J Immunol. 2023 Sep 15;211(6):944-953. doi: 10.4049/jimmunol.2200721.
7
Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.皮下或静脉注射后人源化 CD20 小鼠体内奥法妥木单抗和奥瑞珠单抗的分布和疗效。
Front Immunol. 2022 Jul 28;13:814064. doi: 10.3389/fimmu.2022.814064. eCollection 2022.
8
Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.奥瑞珠单抗治疗活跃期原发性进展型多发性硬化症患者的临床结局及治疗应答的免疫标志物研究。
Cells. 2022 Jun 17;11(12):1959. doi: 10.3390/cells11121959.
9
Antigen-Presenting B Cells Program the Efferent Lymph T Helper Cell Response.抗原呈递 B 细胞规划传出性淋巴辅助性 T 细胞应答。
Front Immunol. 2022 Mar 9;13:813203. doi: 10.3389/fimmu.2022.813203. eCollection 2022.
10
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.接受克拉屈滨治疗的多发性硬化症患者保留了预先存在的体液免疫记忆。
Biomedicines. 2021 Oct 31;9(11):1584. doi: 10.3390/biomedicines9111584.
本文引用的文献
1
The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the "MS Microbiome".肠道微生物组在多发性硬化症风险和进展中的作用：朝着“MS 微生物组”的特征描述迈进。
Neurotherapeutics. 2018 Jan;15(1):126-134. doi: 10.1007/s13311-017-0587-y.
2
Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.多发性硬化症患者的肠道微生物组可使小鼠发生自发性自身免疫性脑脊髓炎。
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-10724. doi: 10.1073/pnas.1711233114. Epub 2017 Sep 11.
3
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.多发性硬化症患者的肠道细菌调节人类 T 细胞，并在小鼠模型中加重症状。
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11.
4
Ocrelizumab and Other CD20 B-Cell-Depleting Therapies in Multiple Sclerosis.奥瑞珠单抗和其他多发性硬化症的 CD20 耗竭疗法。
Neurotherapeutics. 2017 Oct;14(4):835-841. doi: 10.1007/s13311-017-0557-4.
5
B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.来自多发性硬化症患者的B细胞在体外通过凋亡诱导神经元细胞死亡。
J Neuroimmunol. 2017 Aug 15;309:88-99. doi: 10.1016/j.jneuroim.2017.05.004. Epub 2017 May 17.
6
Regulation of humoral immunity by gut microbial products.肠道微生物产物对体液免疫的调节
Gut Microbes. 2017 Jul 4;8(4):392-399. doi: 10.1080/19490976.2017.1299311. Epub 2017 Feb 28.
7
Ocrelizumab in multiple sclerosis: markers and mechanisms.奥瑞珠单抗治疗多发性硬化症：标志物与机制
Lancet Neurol. 2017 Apr;16(4):259-261. doi: 10.1016/S1474-4422(17)30048-0.
8
IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.在克罗恩病脊柱关节炎中富集的IgA包被物会促进T17依赖性炎症。
Sci Transl Med. 2017 Feb 8;9(376). doi: 10.1126/scitranslmed.aaf9655.
9
Onset of secondary progressive MS after long-term rituximab therapy - a case report.长期使用利妥昔单抗治疗后出现继发进展型多发性硬化症——一例病例报告
Ann Clin Transl Neurol. 2016 Dec 20;4(1):46-52. doi: 10.1002/acn3.377. eCollection 2017 Jan.
10
Influence of the Gut Microbiome on Autoimmunity in the Central Nervous System.肠道微生物群对中枢神经系统自身免疫的影响。
J Immunol. 2017 Jan 15;198(2):596-604. doi: 10.4049/jimmunol.1601438.
Zotero 插件